MedTrace Logo

CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases

NCT02058953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2019-10-04

No results posted yet for this study

Summary

The purpose of this study is to collect and bank samples of blood and tissues (such as brain tissue or lymph nodes), as well as cerebrospinal fluid (CSF), which is the fluid that bathes and cushions the spinal cord. The investigator will analyze DNA biomarkers in the samples. The investigator hopes that by studying the biomarkers, he can develop tests in the future that can detect central nervous system (CNS) metastasis in blood samples before they show up on x-ray and develop medicines that can specifically target CNS metastasis.

Conditions

Interventions

PROCEDURE

Craniotomy scheduled

Resection of affected brain tissue

PROCEDURE

Collection for non-craniotomy

CSF, Blood, biopsy

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • John Kirkwood, MD · University of Pittsburgh Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-12
Primary Completion
2019-08-19
Completion
2019-08-19

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02058953 on ClinicalTrials.gov